Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
By mimicking the effects of GLP-1, semaglutide helps regulate blood sugar levels, leading to weight loss and improved metabolic function
Q3 2024: Eli Lilly receives European Commission approval for Zepbound (tirzepatide) for chronic weight management The European Commission granted marketing authorization to Eli Lillys Zepbound, a GLP-1/GIP dual agonist, for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity
Two common billing errors arise here: Billing 4 units for a 2 mg dose
Insurance Barriers: May not cover for weight loss (only approved for diabetes) Requires type 2 diabetes diagnosis for coverage Extensive prior authorization requirements May require trying other medications first High copays even with coverage Supply Shortages: Both Mounjaro and Zepbound have experienced periodic shortages since launch, making consistent access difficult
US$ 23.32
US$ 22.68
US$ 26.43
US$ 25.01
